President Xi Jinping emphasized that “the people’s aspiration for a better life is our ultimate goal”, underscoring maternal and child health as a national priority. With the implementation of China’s three-child policy, demand for advanced women’s and children’s healthcare has intensified. Shenzhen Maternity and Child Healthcare Hospital, the city’s first Class Ⅲ Grade A (China’s highest accreditation tier) specialized institution, leads in clinical services, scientific innovation, and preventive medicine, driving maternal and child health advancements across Shenzhen and the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).
The Loop Laboratory of Shenzhen Maternal and Child Health Medical Research Institute, Loop subcenter of Shenzhen Clinical Medical Research Center for Obstetrics and Reproductive Diseases complements existing regional healthcare networks, aligning with the strategic goals outlined in the GBA Development Plan. By integrating clinical resources with translational research, the center fosters cross-border collaboration in pharmaceutical innovation and interdisciplinary synergy, accelerating the GBA’s transformation into a global scientific hub. Through consolidating cutting-edge research capabilities and facilitating technology transfer, it advances precision healthcare solutions and contributes to building a high-quality living ecosystem for families in the region.
Premature Ovarian Failure (POF) refers to the onset of ovarian function decline in women before the age of 40, characterized by amenorrhea, elevated levels of follicle-stimulating hormone (FSH), and reduced estrogen levels. This condition not only compromises fertility but may also lead to endocrine disorders and premature onset of menopausal symptoms. Stem cell therapy and gene therapy have shown potential to delay disease progression, improving patients' quality of life and restoring reproductive capacity.
In China, the population incidence of preeclampsia ranges from 5.6% to 9.4%. It is defined as a pregnancy-specific disorder typically occurring after 20 weeks of gestation, characterized by two main clinical features: (1) New-onset hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), (2) At least one new-onset complication (proteinuria, placental dysfunction, or other maternal organ dysfunction).
Through pathogenic gene identification and prenatal diagnosis, high-risk fetuses can be early detected, providing families with genetic counseling and decision-making support. Current research demonstrates that gene sequencing technologies exhibit high efficiency and accuracy in pathogenic gene identification and prenatal diagnosis, serving as critical tools for preventing and managing these conditions.
All Contents ©2025 AAAR. All Rights Reserved.
